Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Apr 22, 2024 → Oct 15, 2025

NCT ID

NCT06400511

About Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment

Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment is a phase 3 stage product being developed by Viatris for Blepharitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT06400511. Target conditions include Blepharitis.

What happened to similar drugs?

5 of 9 similar drugs in Blepharitis were approved

Approved (5) Terminated (0) Active (4)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

✅AzaSite®MerckApproved

🔄TP-03 + TP-03 VehicleTarsus PharmaceuticalsPhase 3

🔄Lotilaner + Vehicle ControlLianBioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06400511	Phase 3	Terminated	Apr 22, 2024	Oct 15, 2025	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03 + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 3	34
TP-03, 0.25% + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 2/3	32
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Azithromycin ophthalmic solution, 1% + Vehicle	Merck	Phase 2	27
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25